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Abstract
Background: The increased reports of ESBL dissemination from various centres in south western, Nigeria and the recent
emergence of  carbapenem resistant bacteria prompted the conception of  this study.
Objectives: To demonstrate the relationship between high molecular weight plasmids and the expression of  antibiotic
multi-resistance including ESBL and carbapenemase.
Methods: We investigated 97 isolates of  selected organisms consisting of  67 E. coli and 30 Klebseilla spp for the presence of
plasmids expressing ESBL including carbapenem-hydrolysing enzymes. Beta-lactamase was determined using acidometric
method, while ESBL and carbapenemase activity was determined using the double-disk diffusion test as well as the
Modified Hodge test (MHT). Plasmid profiles of ESBL and carbapenemase positive isolates were determined according to
standard protocols.
Results: An ESBL prevalence rate of 21.6% and carbapenem- resistance rate of 9.3% was recorded. Antibiotic susceptibility
profile of ESBL isolates showed 100.0% resistance against Amoxicillin, Cotrimoxazole and Erythromycin. Moderate
susceptibility was recorded against the Quinolone class of antibiotics; Meropenem remained the most active antibiotic
against ESBL isolates with 62.5% against E. coli and 60% against K. pneumoniae. The plasmid profiles of our study isolates
ranged from 11.8kbp to 35.5kbp.
Conclusion: Due to the relationship between high molecular weight plasmids and multi-drug resistance, we hereby
recommend regular molecular surveillance of  this form in our study setting.
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There has been a global increase in the occurrence
of carbapenem, hydrolysing â-lactamases among
bacterial isolates from different clinical sites1. Majority
of the bacteria isolates that harbour this enzyme are
of the class enterobacteriaceae, which are able to
inhabit the human intestinal tract as commensals2,
these group of bacteria are able to spread easily
between humans through hand carriage and
contaminated food and water causing large
outbreaks2, and are also capable of acquiring genetic
material through horizontal gene transfer3. The first
carbapenemase producer in Enteriobacteriaceae
(NmcA) was identified in 1993 from an isolate of
Enterobacter clocae1. Cabapenemases are mainly of the
Ambler class A penicillinase or Ambler class B
metallo-enzyme groups, or class D enzymes4, there
is also the rare chromosome encoded class C
enzymes. All these groups of  enzymes are capable
of hydrolyzing virtually all the â-lactam antibiotics
including the 3rd generation cephalosporins and
carbapenems.
In Nigeria there have been reports of
carbapenemase producing clinical isolates of enteric
bacteria particularly among E. coli and Klebsiella spp5.
In addition regular reports of various infections with
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ESBL organisms have been recorded in our
environment; there has also been laboratory evidence
of co-acquisition of muti-resistant plasmids in
clinical isolates of E. coli and other enteric organisms
from Abeokuta2-3. This has most undoubtedly put
Abeokuta on the global antibiotic multi-drug resistant
map. Previous reports have indicated the usefulness
of  plasmid profiling in categorising and determining
the extent of antibiotic multi-drug resistance and risk
of epidemic spread3,6-7. These reports have shown
that community colonisation and other reservoir
sources such as food animals are capable of
conjugative spread of these R-plasmids with ESBL
and carbapenemase activity within the hospital
community to cause nosocomial outbreaks2, the
implication of this on the community and National
public health system can be enormous because of
the cost of treating affected patients and managing
outbreaks. Therefore the essence of  maintaining a
log of Epidemiological record of multi-resistant
isolates to include their possible plasmid profiles,
conjugative activity and molecular epidemiology is
essential in our study setting.
It was this need of basic molecular evidence
of transmissible genetic material capable of
conferring carbapenemase and or ESBL activity on
their carrier bacteria isolates that prompted the
inception of  this study. Our objective was therefore
to demonstrate the relationship between high
molecular weight plasmids and the expression of




A total of 97 isolates were recovered from various
clinical samples consisting of 67 E. coli and 30 Klebsiella
spp. Isolates were recovered using standard
Microbiological techniques and identified by gram
reaction and biochemical tests8-9.
Beta lactamase testing
Beta-lactamase production was determined by the
starch iodide acidometric method as described by
Odugbemi et al.10 and further identified by the
modified method of Stokes and Ridgway11.
ESBL detection
Beta lactamase positive isolates were further tested
for the production of ESBL enzymes by the disc
diffusion method using the NCCLS
recommendations for non-fastidious bacteria12-13, by
placing ceftazidime (30µg), cefotaxime (30µg) disc
alone and placing the same discs in combination with
Clavunalic acid (10µg) (Oxiod UK) placed 20mm
apart. A differed of >5mm between the zones of
inhibition of the discs in combination with clavunalic
acid and those alone were considered positive for
ESBL production. Control isolates used were E. coli
ATTC 25922 and Klebseilla pneumonia ATCC 70603.
Carbapenemase detection
Detection of carbapenemase enzyme activity was
done following the modified hodge test (MHT), as
described by Landman et al.14. Briefly 0.5 McFarland
suspension of each tested isolate was inoculated on
fresh Muller-hinton agar and a 10µg Imipenem disk
(Oxoid UK) was placed at the center of the plate
touching the edge of each streaked isolate and
incubated for 18-24hrs at 370c. Interpretation was
done with accordance with CLSI
recommendations15.
Antibiotic susceptibility testing
Antibiotic susceptibility testing was done following
the Kirby-bauer technique for disk diffusion9.
Antibiotics tested include Amoxicillin (30µg), Co-
trimoxazole(10µg), Erythromycin (10µg), Tetracyclin
(30µg),Gentamycin (10µg), Amoxy-clav (30µg),
Ofloxacin (10µg), Nitrofurantion(30µg), Cefuroxime
(30µg), Ceftazidime (30µg) and Meropenem(10µg).
The results from the zone of inhibition were
interpreted according to CLSI guideline15.
Plasmid profiling
Plasmid DNA from each tested ESBL and
carbapenemase producing isolate was extracted using
the alkaline lysis method previously described by
Akinduti et al.3 and Bradford et al.16. Extracted DNA
plasmids were electropherosed on 0.8% Agarose gel,
and stained with 14µl/g Ethidium bromide, gel
pictures were photograghed with a Polariod camera
under the view of  a UV transilluminator. Molecular
weights and distances were determined according
to Kim et al.17.
Results
About 97 isolates were recovered from various
clinical sites consisting 67 isolates of Escherichia coli
and 30 Klebseilla spp. Table 1 shows the age and gender
distribution of tested isolates in relation to
carbapenemase and ESBL production.
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Table 1: Age and Gender distribution of  ESBL and Carbapenemase producing strains of  Escherichia
coli and Klebsiella spp in Abeokuta, Nigeria
Characteristic No. tested (%) Â-lac pos (%) ESBL pos (%) Carb pos (%)
Age (years)
>1-14 27(27.8) 12(44.4) 9(33.3) 3(11.1)
15 – 44 52(53.6) 18(34.6) 9(17.3) 4(7.7)
45 and above 18(18.6) 9(50.0) 3(16.7) 2(11.1)
Gender
Male 44(45.4) 18(40.9) 9(20.5) 4(9.1)
Female 53(54.6) 21(39.6) 12(22.6) 5(9.4)
Total 97(100.0) 39(40.2) 21(21.6) 9(9.3)
Table 2 shows the distribution of  ESBL and carbapenemase producing strains of  Escherichia coli and Klebisella
spp in relation to sample type/anatomical site. From the table, urine was the most frequently isolated sample
site with 43 (44.3%), followed by Blood 13 (13.3%), and lastly CSF 3 (3%).
Table 2: Distribution of  ESBL and Carbapenemase producers in relation to Sample type/Anatomical
site
Sample type No. tested (%) Â-lact producer (%) ESBL producer (%) Carb
                                producer (%)
Blood 13(13.4) 3(23.0) 2(15.4) 1(7.7)
Urine 43(44.3) 20(46.5) 7(16.3) 3(7.0)
Csf 3(3.0) 1(3.3) 0(0.0) 0(0.0)
Genitals 4(4.1) 2(50.0) 2(50.0) 0(0.0)
Others 34(35.2) 13(38.2) 10(29.4) 5(14.7)
Total 97(100.0) 39(40.2) 29(29.9) 9(9.3)
Table 3 shows the Antibiotic susceptibility profile of  ESBL producers to the most commonly used antibiotics
including carbapenem.
Table 3: Antibiotic susceptibility profile of  ESBL producers to various antibiotics
Antibiotic n (%)
Isolate Amox Cot Gen Ery Nit Oflox Am/Clv Caz Mero
E. coli (n=16) 0 0 6(37.5) 0 9(47.4) 9(47.4) 3(18.8) 7(43.8) 10(62.5)
Kleb spp (n=5) 0 0 1(20) 0 3(60) 1(20) 1(20) 2(40) 3(60)
Amox-Amoxicillin, Cot-Cotrimoxazole, Gen-Gentamycin, Ery-Erythromycin, Nit-Nitrofurantoin, Oflox-
Ofloxacin, Am/Clv-Amoxicillin/Clavunalate, Caz-Ceftraxone, Mero-Meropenem
Table 4 shows the average plasmid sizes of  R-
plasmids of ESBL and carbapenemase isolates of
Escherichia coli and Klebseilla spp, in relation to
anatomical site. From the table below Klebseilla spp
recorded a higher average plasmid weight of
22.1±1.8 as compared with E. coli 20.71±1.8. With
catheter isolates recording the highest plasmid weight
24.3kb
Table 4: Average plasmid sizes of  R-plasmids
of ESBL and Carbapenemase producing
isolates of Escherichia coli and Klebsiella spp
Average plasmid Size (Kb)






Average wt 20.7±2.3 22.1±1.8
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Figure 2: A culture plate showing positive samples using the Modified Hodge test for Carbapenemase
resistance testing on our our isolates (At the center is Imipenem antibiotic disk 10ìg).
M                 2              3             4              5              6            7               8
Figure1: Agarose gel electrophoresis of plasmid DNA recovered from the hospital isolates pathogens.
Lane 1; DNA marker (M): 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0 kb, lane 2, 3, 4, 5, 6, 7 and 8 are the plasmid














The presence and dissemination of ESBL isolates
of E. coli and Klebseilla spp has been established in
Abeokuta, Southwest Nigeria3,18. Recent reports
indicate an increasing upsurge of this pathogen in
Abeokuta; with data bordering on epidemic values
particularly in institutionalised settings (Motayo
unpublished data). Our current study was targeted
at determining molecular evidence of  transmissible
plasmids responsible for ESBL and carbapenemase
resistance by plasmid profiling of  isolates. In our
current study, 97 isolates comprising 67 E. coli and
30 Klebsiella spp. were tested with an ESBL prevalence
rate of 21.6% and carbapenemase resistance rate of
9.3%. This is higher than a previous report by Olowe
and Aboderin18 which reported a prevalence rate
of 9.0% for ESBL producers at FMC, Abeokuta.
It is lower than a similar report from the same study
environment which reported a rate of 27.3% ESBL
prevalence among enteric isolates3. Our results are
also far lower than the report of Iroha et al.19 which
reported a prevalence of 56.6% ESBL production
in Klebsiella spp. isolates from blood and urine in
ESUTH Enugu Southeastern Nigeria. Iroha et al.19
also reported a 59.4% ESBL production in E. coli
isolates from blood and urine in ESUTH Enugu
Southeastern Nigeria. This shows the extent of
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epidemic spread the ESBL resistance phenotype is
taking particularly in Southern Nigerian Hospital
settings.
From our generated data, there was no
statistically significant difference of â-lactamase
producers in relation to gender (p>0.05). There was
significantly higher prevalence of both ESBL and
carbapenemase phenotype in the age extremes. The
distribution of ESBL and carbapenemase resistant
isolates in relation to anatomical site revealed that
the highest prevalence of ESBL resistance was from
genital samples (50.0%). This was followed by urine
(16.3%) and lastly blood with 15.4%. Our data reveals
a high degree of ESBL resistance among isolates
from blood. This has serious clinical consequences,
as these resistance conferred on this isolates in blood
will increase risk of medical complication such as
sepsis, renal failure and death if appropriate antibiotic
is not administered quickly20. Also ESBL resistance
often leads to increased hospital length of stay and
financial burden in terms of  cost of  treatment.
The current study highlights an emerging
trend of carbapenemase resistance in our study setting
with 7.7% prevalence in urine isolates and 7.0% in
isolates from blood cultures. These posses a potential
public health threat, as only few antibiotics has been
shown to be effective against carbapenem-resistant
bacteria. And these are not available in our
environment. The value reported in our study is
higher than that of a recent study done at Abeokuta,
which reported a carbapenemase-resistance rate of
2.3%3.
Antibiotic susceptibility profile of the ESBL
positive isolates revealed a 100.0% resistance against
amoxicillin, cotrimoxazole and erythromycin. Our
result is in agreement with several previous reports
on high level of â-lactam and macrolide resistance
in enteriobacteriaceae from our region2,5,18. Moderate
susceptibility was recorded against the quinolone class
of antibiotics (ofloxacin) with 47.4% in E. coli and
20.0% for Klebsiella spp. This shows that there is still
some degree of efficacy displayed by this brand of
antibiotics despite its wide misuse21. Nitrofurantoin,
a bacteriostatic agent displayed a fairly good
susceptibility profile against our ESBL isolates. The
only limitation to this is that, it is only prescribed
mainly against urinary tract infections and under
specific conditions because of its toxic effects22.
Poor susceptibility was recorded by
amoxicillin/clavunalate, with E. coli having only
18.8%. Average susceptibility was recorded for
ceftrazone with E. coli having 48.8% susceptibility.
This is in agreement with previous reports which
highlighted the various degrees of  intermediate
susceptibility displayed by some classes of ESBL
producing bacteria such as the AmpC and OXA
types7,23. Naturally, the carbapenem drug
meropenem recorded the highest susceptibility level
(62.5%). This shows that this class of drug still remains
the drug of choice in treating severe infections with
ESBL agents. The only challenge remains lack of
availability and high cost of  procuring these drugs.
Although our study reveals an emerging danger with
carbapenem-resistance of up to 40.0%, greater
attention has to be paid to regular surveillance of
antibiotic drug resistance.
From the plasmid profiling of isolates, the
study revealed a very high plasmid profile ranging
from 11.8kbp to 35.5kbp. This is higher than
previous reports on R-plasmids in south-western
Nigeria. For instance, in a study done at Lagos
University Teaching Hospital by Adenipekun et al.7,
plasmid sizes ranged from 3.0kbp to 4.9kbp. The
relatively large plasmid sizes observed in this study
can be directly attributable to multiple genes coding
for various resistant phenotypes. This results in
resistance to 2 or more classes of antibiotics as
observed in this current study. Previous reports such
that of Kim et al.17 have supported this finding, and
molecular evidence have shown this to be common
in most R-plasmids showing resistance to 2 or more
classes of antibiotics24.
Conclusion
This study has revealed the presence of isolates with
very high molecular weight plasmids harbouring
ESBL and carbapenemase-resistant genes. It also
showed the presence of possibly co-acquired
macrolide and other unidentified resistant genes. The
public health implication of continuous dissemination
of such multi-resistant bacteria with high frequency
transmissible DNA cannot be overlooked. With the
increased attention being paid to stricter infection
control practices across our country2,25, it is pertinent
to note that health authorities as a matter of urgency
should include molecular epidemiology in its
infection control policy. This is in order to detect
changing patterns and emergence of new resistance
genes before wide spreads dissemination occurs.
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